Publications by authors named "C Gaber"
Introduction: Abiraterone and enzalutamide are both approved in the United States for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The objective of this study was to compare the real-world effectiveness and cardiovascular safety of these agents, drawing from a cohort of older adult patients diagnosed with mCRPC.
Materials And Methods: The Surveillance, Epidemiology, and End Results-Medicare database was used to conduct an observational study comparing three-year overall survival and one-year risk of major adverse cardiovascular events (MACE) between initiators of abiraterone or enzalutamide between September 2012 and June 2017.
Article Synopsis
- - Regulators and healthcare providers are exploring observational studies using real-world data (RWD) to enhance decision-making in oncology, aiming to complement traditional clinical trial evidence while addressing potential biases.
- - The clone-censor-weight (CCW) method is introduced to help cancer researchers understand and implement a structured approach to mitigate immortal time and other biases in RWD studies, using visuals and relevant examples for clarity.
- - This method effectively manages complex patient data by creating duplicate patient populations, applying treatment strategies, and adjusting for biases caused by artificial censoring, making RWD studies more reliable and comparable to randomized trials.
Prevalence and Costs of Esophageal Strictures in the United States.
Clin Gastroenterol Hepatol
September 2024
Background & Aims: Esophageal strictures are a leading cause of dysphagia, but data regarding the epidemiology of esophageal strictures are limited. This study aimed to investigate the prevalence, health care utilization, and financial burden of esophageal strictures in the United States.
Methods: We performed a retrospective cohort study using 2 large national insurance claims databases (MarketScan and Medicare).
Background: Neoadjuvant chemoradiation and chemotherapy are recommended for the treatment of nonmetastatic esophageal cancer. The benefit of neoadjuvant treatment is mostly limited to patients who exhibit pathologic complete response (pCR). Existing estimates of pCR rates among patients receiving neoadjuvant therapy have not been synthesized and lack precision.
View Article and Find Full Text PDFIntroduction: In the United States, clinical guidelines recommend daily use of proton pump inhibitors (PPIs) amongst individuals diagnosed with Barrett's esophagus to decrease the risk of progression to dysplasia and neoplasia. Prior studies documenting adherence to PPIs in this population have not characterized heterogeneity in adherence patterns. Factors that may relate to adherence are incompletely described.
View Article and Find Full Text PDF